To describe anatomical changes in the retina and choroid following the administration of PF-04523655 [ Time Frame: Day 14 ] [ Designated as safety issue: Yes ]

To determine the changes in visual acuity ETDRS chart after a single intravitreal injection of PF-04523655 [ Time Frame: Day 14 ] [ Designated as safety issue: Yes ]

To evaluate the safety, efficacy and frequency of dosing following administration of PF-04523655 of approved VEGF-inhibitors in those study patients requiring rescue therapy [ Time Frame: Monthly ] [ Designated as safety issue: Yes ]

To evaluate early response after a single intravitreal administration of PF-04523655 in patients who, in the opinion of the investigator, have the potential to show improvement in visual acuity from other treatment options (Stratum 2 patients) [ Time Frame: Day 14 ] [ Designated as safety issue: Yes ]

Patient is of childbearing potential. Every female patient is considered of child-bearing potential unless she has had sterilization surgery or is post-menopausal and has not had a menstrual period for at least 12 months.

Patient has CNV due to causes other than AMD, including ocular or periocular infections.

Patient has lesions not easily imaged and quantified.

Patient has underlying systemic disease such as cardiac, neurological, infectious disease, uncontrolled diabetes mellitis, or disease of the eye other than AMD. Patient may have medically controlled glaucoma.

Patient is participating in any concurrent interventional study.

Gender

Both

Ages

50 Years and older (Adult, Senior)

Accepts Healthy Volunteers

No

Contacts ICMJE

Contact information is only displayed when the study is recruiting subjects